Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ

Watchlist Manager
Eckert & Ziegler Strahlen und Medizintechnik AG Logo
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Watchlist
Price: 39.88 EUR 7.84% Market Closed
Market Cap: 831.3m EUR
Have any thoughts about
Eckert & Ziegler Strahlen und Medizintechnik AG?
Write Note

Eckert & Ziegler Strahlen und Medizintechnik AG
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eckert & Ziegler Strahlen und Medizintechnik AG
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Gross Profit
€206.4m
CAGR 3-Years
29%
CAGR 5-Years
19%
CAGR 10-Years
13%
Carl Zeiss Meditec AG
XETRA:AFX
Gross Profit
€1.1B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
9%
Stratec SE
XETRA:SBS
Gross Profit
€67.8m
CAGR 3-Years
-9%
CAGR 5-Years
6%
CAGR 10-Years
3%
Siemens Healthineers AG
XETRA:SHL
Gross Profit
€8.4B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Gross Profit
€1.5B
CAGR 3-Years
-5%
CAGR 5-Years
4%
CAGR 10-Years
3%
Sartorius AG
XETRA:SRT
Gross Profit
€1.5B
CAGR 3-Years
-5%
CAGR 5-Years
10%
CAGR 10-Years
15%
No Stocks Found

Eckert & Ziegler Strahlen und Medizintechnik AG
Glance View

Market Cap
831.3m EUR
Industry
Health Care

Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.

EUZ Intrinsic Value
56.66 EUR
Undervaluation 30%
Intrinsic Value
Price

See Also

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Gross Profit?
Gross Profit
206.4m EUR

Based on the financial report for Sep 30, 2024, Eckert & Ziegler Strahlen und Medizintechnik AG's Gross Profit amounts to 206.4m EUR.

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Gross Profit growth rate?
Gross Profit CAGR 10Y
13%

Over the last year, the Gross Profit growth was 84%. The average annual Gross Profit growth rates for Eckert & Ziegler Strahlen und Medizintechnik AG have been 29% over the past three years , 19% over the past five years , and 13% over the past ten years .

Back to Top